Physician profile
Leland J Sherlock
NPI 1790758142
$4,137.13
in general payments reported to CMS, 2019-2025
21 companies · $563 in 2025
The $563 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $498 · 2021: $858 · 2022: $579 · 2023: $333 · 2024: $810 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,705.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $938.75 | 2019-2021 | |
| Abbvie INC. | $564.56 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $485.36 | 2022-2025 | Rocklatan, Eysuvis, Tryptyr |
| Kala Pharmaceuticals, INC. | $354.21 | 2019-2022 | |
| Alimera Sciences, INC. | $333.31 | 2024 | Yutiq, Iluvien |
| Bausch & Lomb Americas INC. | $280.98 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $211.32 | 2019-2022 | |
| Allergan, INC. | $205.84 | 2019-2022 | |
| Shire North American Group INC | $128.46 | 2019 | |
| Amgen INC. | $117.07 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $92.43 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $88.84 | 2019-2021 | |
| Sight Sciences, INC. | $63.51 | 2021-2023 | Omni Surgical System |
| Apellis Pharmaceuticals, INC. | $49.23 | 2024 | Syfovre |
| Novartis Pharmaceuticals Corporation | $48.98 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $44.19 | 2022-2024 | Iyuzeh |
| Akorn Operating Company LLC | $37.34 | 2021 | |
| Mallinckrodt Hospital Products INC. | $35.90 | 2025 | Acthar |
| Horizon Therapeutics Plc | $25.23 | 2022 | |
| Eyevance Pharmaceuticals LLC | $15.96 | 2022 | |
| Dompe US, INC. | $15.66 | 2024 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leland Sherlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.